A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

Italy

ASST Papa Giovanni XXIII Piazza OMS, Bergamo, Bergamo

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Milano

Istituto Europeo di Oncologia, Milan, Milano

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Via Mariano Semmola, Naples, Napoli